CERK and non-small cell lung carcinoma: NSCLC cell lines with mutant KRAS exhibited significantly lower survival rates upon treatment with the CERK inhibitor NVP-231 compared to those with wild-type KRAS, indicating a specific vulnerability of KRAS-mutated cells to CERK inhibition.